CMBCC Co-High Medical Investment Fund

CMBC Capital Co-High Medical Investment Fund (also known as CMBCC Co-High Medical Investment Fund SP) was a healthcare-focused investment vehicle established as a segregated portfolio under the management of Co-High Investment Management and controlled by CMBC Capital Holdings. The fund specialized in growth-stage life science companies, particularly those with innovative technologies in the Greater China region and globally. Its portfolio included investments in biotechnology and medical device companies such as Promethera Biosciences and Broncus Medical. The fund aimed to bridge international healthcare innovations with the Chinese market through strategic capital and industry partnerships. As of late 2023, CMBC Capital had exited its interest in the fund through the redemption or disposal of its participating shares.